HOME >> BIOLOGY >> NEWS
Newly-discovered class of genes determines and restricts stem cell fate

(Philadelphia, PA) Research on adult stem cells found in the skin hints at a new class of genes, according to a study from investigators at the University of Pennsylvania School of Medicine. These genes dubbed pangenes can both govern a stem cell's fate and put a hold on future differentiation until the time is right. Understanding the molecular control of these genes has implications for therapies that involve tissue regeneration.

The researchers found that Pax3, a gene critical in embryonic development of melanocytes cells that make and store the pigments in the skin and hair is also expressed in adult stem cells in the skin.

"Our findings told us that a recapitulation of an embryonic program is occurring in resident stem cells in adult skin," explains Jon Epstein, MD, Professor of Medicine, Cardiovascular Division. "These few rare stem cells were expressing genes that previously had only been known to be expressed in a developing embryo. That was the first clue that we were on to something new." Epstein and colleagues report their findings in the February 24th issue of Nature.

The scientists found that Pax3 plays dual and somewhat seemingly contradictory roles in adult stem cells: it directs them to become melanocytes, but simultaneously prevents them from differentiating completely. "It gets the show going, but at the same time, prevents the final act," says Epstein. "I call this dual function a "biological capacitor," because Pax3 tells the cell: Get ready to go, but at the same time won't let it proceed."

Pangenes Express Behavioral Qualities of Pan and Peter Pan

Epstein notes that this research is conceptually new since he suggests that a single gene can both tell a cell what it should become and restrict its fate by preventing differentiation. The ability of a single biochemical factor or complex of factors to have this dual role may represent a new general paradigm for developmental and stem
'"/>

Contact: Ed Federico
ed.federico@uphs.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
23-Feb-2005


Page: 1 2

Related biology news :

1. Damon Runyon names new class of rising stars in cancer research
2. Pendulum love, science class gender gaps, musical mind mirrors, and unparticle physics
3. New algorithms classify outcomes of nonsmall cell lung cancer patients
4. UCLA molecular biologists convert protein sequences into classical music
5. Double honor recognises world-class science and spin-out success
6. Misclassified for centuries, medicinal leeches found to be 3 distinct species
7. Fighting to keep Darwin in the classroom
8. Funding boost for QUT world-class banana research
9. Protein folding physics, nanohandles, sunscreen for algae and classical quantum weirdness
10. New understanding of COX-1 and COX-2 enzymes could revise classification of pain meds
11. Free access to world-class biological databases for European science thanks to FELICS

Post Your Comments:
(Date:10/17/2014)... news release is available in German . ... only a very few drugs. When treating overdoses, doctors are ... is especially difficult if there is a combination of drugs ... playing and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe ... wanted to find an answer to this question. "The task ...
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2
(Date:10/22/2014)... BOSTON , Oct. 22, 2014 /PRNewswire/ ... global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, ... option to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, ... agonist, for the treatment of diabetic gastroparesis and other ... a successful Phase 2 trial of relamorelin for the ...
(Date:10/22/2014)... Cranford, NJ (PRWEB) October 22, 2014 ... technologies and services – has been working with a ... Health and New Haven Farms Community Farming Collaborative to ... iPad-based ePRO solution. The study, which started in ... Wellness program that provides participants weekly exposure to and ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
Cached News: